| Name | Title | Contact Details |
|---|---|---|
Rebecca Myers |
Founder and Chief Executive Officer | Profile |
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.
Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer`s, Parkinson`s, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.
Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.